How Much Weight Do People Typically Lose on Wegovy?

Last reviewed: June 20, 2026

Last updated: June 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, the active ingredient in Wegovy, produced average weight loss of 15% in pivotal clinical trials—roughly 22 pounds for a person weighing 150 pounds. Many patients wonder what realistic outcomes look like and whether prescription GLP-1 therapy fits their weight loss goals. PlexusDx delivers clinically-proven semaglutide from licensed 503A compounding pharmacies at $189/mo month-to-month, or from $149/mo on the 6-month plan, making personalized weight loss accessible to all 50 states.

Clinical Trial Results for Semaglutide Weight Loss

The landmark STEP trials evaluated semaglutide's effectiveness over 68 weeks in adults with obesity or overweight with at least one weight-related condition. Participants receiving the highest maintenance dose lost approximately 15% of their baseline body weight on average, compared to 2.4% in the placebo group. This 12-percentage-point difference demonstrates semaglutide's ability to produce clinically meaningful weight reduction beyond diet and exercise alone.

Individual results vary based on genetics, adherence, lifestyle factors, and starting dose. Some trial participants achieved greater than 20% weight loss, while others saw modest reductions in the 5-10% range. The dose-escalation protocol used in clinical trials—starting low and increasing gradually—mirrors how PlexusDx physicians manage treatment to balance efficacy and tolerability.

How Individual Weight Loss Varies on Semaglutide

The PlexusDx Precision Peptide Genetic Test analyzes FTO (rs9939609) and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Body composition, starting weight, and concurrent lifestyle changes also shape outcomes. A 200-pound person may lose 30 pounds while a 150-pound person on the same dose loses 15 pounds. Consistent adherence to injection schedules, increased physical activity, and sustained dietary improvements amplify weight loss beyond medication alone.

Semaglutide Weight Loss Timeline: What to Expect

Most patients begin noticing appetite reduction within the first two weeks of starting semaglutide, though meaningful weight loss typically appears after 4-8 weeks. Weekly weigh-ins are less reliable indicators than monthly trends, as water retention and normal fluctuation can mask progress. By week 12-16, many patients report losing 5-10 pounds and experiencing sustained fullness from smaller meals.

Peak weight loss usually occurs between months 4 and 6, as doses reach therapeutic levels and lifestyle habits solidify. PlexusDx supports this timeline through structured dose escalation protocols—starting at low doses to minimize side effects while gradually increasing to the therapeutic range where maximum efficacy emerges. Continued weight loss beyond six months is possible with sustained treatment and behavioral consistency.

PlexusDx Semaglutide vs. Branded Wegovy: Clinical Equivalence

Compounded semaglutide from licensed 503A pharmacies contains the identical active pharmaceutical ingredient as brand-name Wegovy, manufactured under strict quality standards and FDA oversight. Both delivery mechanisms—branded pens and compounded syringes—produce the same biological effect when dosed correctly. The difference lies in cost: PlexusDx semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan, compared to branded Wegovy's typical $935-$1,299 cash price.

PlexusDx operates in all 50 states without insurance requirements, membership fees, or authorization delays. HSA and FSA accounts cover treatment, expanding accessibility for patients with tax-advantaged savings. Personalized dosing protocols and optional Precision Peptide Genetic Testing help identify whether semaglutide alone, combination therapy, or alternative peptide approaches best align with individual metabolism and genetic predispositions.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is 15% weight loss realistic for me on semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

How long does it take to see weight loss results on semaglutide?

Most patients experience appetite suppression within 1-2 weeks and measurable weight loss by week 4-8. Significant results typically appear between months 3-6 as doses reach therapeutic levels. PlexusDx supports structured dose escalation to balance safety and efficacy, meaning your dose may increase over time—but your price remains flat at $189 per month.

Can I afford semaglutide without insurance?

PlexusDx semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan with no membership fees, insurance requirement, or hidden costs. Treatment qualifies for HSA and FSA accounts, reducing your net expense further. Unlike branded Wegovy at $900+, compounded semaglutide from licensed 503A pharmacies delivers clinical equivalence at an accessible price across all 50 states.

What happens if I stop losing weight on semaglutide?

Weight-loss plateaus occur when the body adapts to medication and calorie deficit. Dose increases, lifestyle adjustments, or combination therapy (such as adding tirzepatide via GLP-Squared) can restart progress. PlexusDx physicians monitor your response and adjust your regimen; your subscription price remains stable regardless of dose escalation.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Wegovy For Losing Weight
• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Wegovy Vs Zepbound Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.